BioSpace News Archive

MDxHealth SA, a commercial-stage precision diagnostics company, announced its financial results for the first quarter ended March 31, 2023.

Erasca, Inc. reported financial results for the fiscal quarter ended March 31, 2023, and provided business updates.

VBL Therapeutics, announced financial results for the first quarter ended March 31, 2023, and provided a corporate update.

Ardelyx, Inc. announced that on May 8, 2023, the compensation committee of the company’s board of directors granted two new non-executive employees options to purchase an aggregate of 46,178 shares of the company’s common stock, and granted five new non-executive employees an aggregate of 52,600 Restricted Stock Units.

NightHawk Biosciences, a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing, and commercialization of innovative medical countermeasures that combat unmet and emerging biothreats, provided strategic, financial, and operational updates for the quarter ended March 31, 2023.

Aerovate Therapeutics, Inc. announced financial results for the quarter ended March 31, 2023, and recent business highlights.

Zevra Therapeutics, Inc., a rare disease therapeutics company, provided corporate updates and reported its financial results for the quarter ended March 31, 2023.

Mineralys Therapeutics, Inc. announced financial results for the quarter ending March 31, 2023, and provided a corporate update.

Evoke Pharma, Inc. (NASDAQ: EVOK) today announced its financial results for the first quarter ended March 31, 2023, and recent corporate developments.

INVO Bioscience, Inc., a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture procedure it enables, announced financial results for the quarter ended March 31, 2023 and provided a business update.